Autoimmunity-blocking Antibody for Tolerance in Recently Diagnosed Type 1 Diabetes
Public ClinicalTrials.gov record NCT00129259. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase II Multiple-Dose Treatment of New Onset Type 1 Diabetes Mellitus With Anti-CD3 mAb
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Anti-CD3 monoclonal antibody (a.k.a. hOKT3gamma1 \[Ala-Ala\],teplizumab, MGA031) is a humanized antibody that is commonly used to prevent organ rejection. The purpose of this study is determine whether anti-CD3 mAb treatment can halt the progression of newly diagnosed type 1 diabetes.
Study identification
- NCT ID
- NCT00129259
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 83 participants
Conditions and interventions
Conditions
Interventions
- Anti-CD3 mAb Biological
- Diabetes Standard of Care Treatment Other
- Iron supplementation Dietary Supplement
Biological · Other · Dietary Supplement
Eligibility (public fields only)
- Age range
- 8 Years to 30 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 2005 (Type not available)
- Primary completion
- Mar 2011 (Actual)
- Completion
- Mar 2011 (Actual)
- Last update posted
- May 22, 2017
2005 – 2011
United States locations
- U.S. sites
- 7
- U.S. states
- 6
- U.S. cities
- 6
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| The Diabetes Center at UCSF | San Francisco | California | 94143 | — |
| Barbara Davis Center for Childhood Diabetes | Denver | Colorado | 80262 | — |
| Yale University | New Haven | Connecticut | 06520 | — |
| Medical College of Georgia | Augusta | Georgia | 30912 | — |
| Dept. of Medicine, Division of Endocrinology and the Naomi Berrie Diabetes Center/Columbia University | New York | New York | 10032 | — |
| Benaroya Research Institute | Seattle | Washington | 98108 | — |
| Pacific Northwest Research Institute/University of Washington | Seattle | Washington | 98122 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00129259, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 22, 2017 · Synced Oct 17, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00129259 live on ClinicalTrials.gov.